ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Millennium Management LLC

Millennium Management LLC raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 89.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,002,849 shares of the specialty pharmaceutical company's stock after purchasing an additional 473,097 shares during the quarter. Millennium Management LLC owned about 4.77% of ANI Pharmaceuticals worth $55,437,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. US Bancorp DE raised its position in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the period. KBC Group NV increased its stake in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter worth about $166,000. Bridgefront Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $204,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Analysts Set New Price Targets

ANIP has been the subject of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. Finally, Guggenheim reiterated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $80.13.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares of the company's stock, valued at $4,131,164.80. This trade represents a 1.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the sale, the insider now directly owns 107,317 shares of the company's stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,681 shares of company stock worth $468,698 in the last three months. 11.10% of the stock is owned by insiders.

ANI Pharmaceuticals Stock Down 1.3%

Shares of ANIP stock traded down $0.76 on Thursday, hitting $58.32. The stock had a trading volume of 41,871 shares, compared to its average volume of 299,534. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $77.00. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -106.32 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock's 50 day moving average is $66.76 and its 200-day moving average is $60.79.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. During the same period last year, the firm earned $0.82 earnings per share. The company's revenue was up 43.4% on a year-over-year basis. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.